Jiangbing Zhou, PhD
Cards
Appointments
Contact Info
About
Titles
Professor of Neurosurgery
Biography
Dr. Jiangbing Zhou, Professor of Neurosurgery and Biomedical Engineering, directs a multidisciplinary laboratory with a central focus on the development of translational nanomedicine, gene therapy, and stem cell therapy for treatment of neurological disorders.
Appointments
Neurosurgery
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Associate Research Scientist
- Yale University (2012)
- Postdoctoral Associate
- Yale University (2011)
- PhD
- Johns Hopkins University (2008)
- MS
- Tsinghua University (2001)
- BE
- East China University of Science and Technology (1998)
Research
Overview
Non-viral genome medicine. Our initial endeavors concentrated on engineering nanoparticles (NPs) to enhance encapsulation, cell penetration, and escape from endosomes (Biomaterials, 2012, 2014). Although promising, this approach's complexity posed limitations. To streamline our formulation, we innovated a chemistry technique to synthesize a novel class of terpolymers and their derivative single-component NPs for gene delivery (Nature Materials, 2012; ACS Nano, 2016; Advanced Science, 2020). Further strides included the creation of liposome-templated hydrogel nanoparticles to facilitate efficient CRISPR/Cas9 delivery to the brain (Adv Funct Mater, 2017). In a more recent breakthrough as part of the NIH SCGE program (Nature, 2021), we pioneered a chemical engineering approach that circumvents NPs for delivering genome editing machinery to the brain, resulting in brain-wide neuronal editing. This innovation has been applied to treat a varity of neurogenetic diseases. Presently, the system is undergoing preparation for IND-enabling studies and clinical translation. Building on the success, our current focus centers on developing the next generation of nanoparticles while also pursuing NP-free methodologies for further improved delivery efficiency as well as tissue-specific targeting.
Drug delivery to the brain. Efficient drug delivery to the brain remains a formidable challenge due to the presence of the blood-brain barrier (BBB). To surmount this delivery challenge, we developed brain-penetrating NPs specifically tailored for locoregional drug delivery to the brain, circumventing the BBB (PNAS, 2013), as well as brain-seeking NPs achieved through either intricate multiple-component engineering or a more streamlined single-component design for non-invasive drug delivery to the brain, traversing the BBB (ACS Nano, 2016, 2018; Adv Funct Mater. 2017, 2020; Nature Cell Biology. 2020; Advanced Materials. 2017; Nature Biomedical Engineering. 2020). Leveraging the success of these breakthroughs, our ongoing focus centers on development the next generation of NPs with simplified formulations, as well as the exploration of NP-free methodologies. These innovative strategies hold the potential to revolutionize systemic drug delivery to the brain, and, thus, may lead to a transformative impact on the treatment landscape of various neurological diseases.
Biology of brain cancer. I was among the first pioneering group studying cancer stem cells (CSCs) in solid tumors. My early-stage work provided substantial evidence about the importance of CSCs in cancer treatment and suggested directions in achieving their preferential elimination (PNAS, 2007; BCRT, 2008, 2009). Leveraging my collaboration with esteemed neurosurgeon colleagues, we have recently established a comprehensive array of resources dedicated to brain cancer research. Building on these resources, we performed a genome-wide RNAi screen and identified several novel genes, which regulate BSCS differentiation and migration, and completed a large-scale drug screen on multiple BCSCs (Advanced Science. 2019, Neuro-Oncology, 2022; Nature Communications. 2022). Currently, our primary focus revolves around in-depth investigations of these lead candidate genes and identified drugs. Our overarching objective is to unravel their therapeutic potential, with the ultimate goal of develop novel approaches for the treatment of brain cancer.
Nanomaterials for oral drug delivery. With its convenience and high patient compliance, oral drug delivery remains a preferred method for many patients. In our pursuit of innovative approaches, we took an unconventional route by exploring nature-derived nanomaterials. This led us to discover a group of small molecules forming supramolecular NPs, some of which show efficient drug encapsulation and gastrointestinal penetration. Inspired by this, we developed novel polymeric materials optimized for oral drug delivery. These materials have proven capable of facilitating oral delivery of various therapeutics, including protein drugs like insulin and antibodies, offering new avenues for disease treatment.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Joseph Piepmeier, MD, FAANS
Mike Ming-Qiang Wenn
Anita Huttner, MD
Jaime Grutzendler, MD
James E. Hansen, MD, MS
Jean-Leon Thomas, PhD
Drug Delivery Systems
Nanoparticles
Brain Neoplasms
Genetic Therapy
Biomedical Engineering
Glioblastoma
Publications
2024
Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment
Ye Z, Sheu W, Qu H, Peng B, Liu J, Zhang L, Yuan F, Wei Y, Zhou J, Chen Q, Xiao X, Zhang S. Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment. Small Science 2024 DOI: 10.1002/smsc.202400081.Peer-Reviewed Original ResearchConceptsBlood-brain barrierBardoxolone methylGlioblastoma multiformeBrain tumorsSurvival of miceSelf-assembled nanoparticlesInhibited GBM tumor growthEnhance drug penetrationGlioblastoma multiforme treatmentKill GBM cellsLack of effective drugsTumor growthDrug penetrationIntravenous administrationP28 peptideEffective drugsGlioblastoma treatmentTumorClinical applicationGBM cellsPeptide-conjugatesTreatmentBrainBardoxoloneGlioblastomaCorrection: pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis
Fan Z, Zhou S, Garcia C, Fan L, Zhou J. Correction: pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis. Nanoscale 2024, 16: 5442-5442. PMID: 38372010, DOI: 10.1039/d4nr90035a.Peer-Reviewed Original ResearchAltmetric
2023
Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma
Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma. CNS Neuroscience & Therapeutics 2023, 30: e14528. PMID: 38044793, PMCID: PMC11017454, DOI: 10.1111/cns.14528.Peer-Reviewed Original ResearchCitationsAltmetricConceptsBlood-brain barrierP-gp inhibitorsCerebral vascular endothelial cellsStrong anti-tumor effectsCommon primary malignant tumorApplication of paclitaxelEfflux transportersPrimary malignant tumorsUse of paclitaxelEfficacy of paclitaxelAnti-tumor effectsPeripheral solid tumorsCentral nervous systemNatural bioactive moleculesEffective anti-cancer drugsP-gp transporterVascular endothelial cellsBlood concentrationsMalignant tumorsGlioma treatmentNervous systemP-gpAnti-cancer drugsSolid tumorsTumor tissue
2020
LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy
Chen Y, Jiang T, Zhang H, Gou X, Han C, Wang J, Chen AT, Ma J, Liu J, Chen Z, Jing X, Lei H, Wang Z, Bao Y, Baqri M, Zhu Y, Bindra RS, Hansen JE, Dou J, Huang C, Zhou J. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nature Cell Biology 2020, 22: 1276-1285. PMID: 33005030, PMCID: PMC7962994, DOI: 10.1038/s41556-020-00586-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsApoptosisAtaxia Telangiectasia Mutated ProteinsBrain NeoplasmsBreast NeoplasmsCell ProliferationDNA DamageDNA RepairFemaleGamma RaysHumansMiceMice, Inbred BALB CMice, NudeMutS Homolog 2 ProteinNuclear ProteinsPhosphorylationRadiation-Sensitizing AgentsSignal TransductionTumor Cells, CulturedXenograft Model Antitumor AssaysTargeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids
Li S, Su W, Wu H, Yuan T, Yuan C, Liu J, Deng G, Gao X, Chen Z, Bao Y, Yuan F, Zhou S, Tan H, Li Y, Li X, Fan L, Zhu J, Chen AT, Liu F, Zhou Y, Li M, Zhai X, Zhou J. Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids. Nature Biomedical Engineering 2020, 4: 704-716. PMID: 32231314, PMCID: PMC7197249, DOI: 10.1038/s41551-020-0540-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAmino acid transporter 1Orthotopic mouse modelHuman tumor xenograftsLarge neutral amino acid transporter 1Neutral amino acid transporter 1High tumor selectivityTumor burdenMouse modelTumor xenograftsHuman gliomasDetectable toxicityTransporter 1TumorsCancer cellsTumor selectivitySurface moleculesDelivery of chemotherapeuticsTumor-specific imagingMiceDrugsLarge amino acidsAmino acidsImagingDeliveryXenografts
2018
Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides
Yu X, Gou X, Wu P, Han L, Tian D, Du F, Chen Z, Liu F, Deng G, Chen AT, Ma C, Liu J, Hashmi SM, Guo X, Wang X, Zhao H, Liu X, Zhu X, Sheth K, Chen Q, Fan L, Zhou J. Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides. Advanced Materials 2018, 30: e1803888. PMID: 30507051, DOI: 10.1002/adma.201803888.Peer-Reviewed Original ResearchCitationsThrombin-Responsive, Brain-Targeting Nanoparticles for Improved Stroke Therapy
Guo X, Deng G, Liu J, Zou P, Du F, Liu F, Chen AT, Hu R, Li M, Zhang S, Tang Z, Han L, Liu J, Sheth KN, Chen Q, Gou X, Zhou J. Thrombin-Responsive, Brain-Targeting Nanoparticles for Improved Stroke Therapy. ACS Nano 2018, 12: 8723-8732. PMID: 30107729, DOI: 10.1021/acsnano.8b04787.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBrain-targeted nanoparticlesIschemic brainEfficacy of glyburideImproved treatmentIschemic brain tissueEffective pharmacological approachBlood-brain barrierMatrix metalloproteinase-9Ischemic strokeStroke patientsStroke therapyMetalloproteinase-9Current treatmentPharmacological approachesBrain tissueIschemic microenvironmentTherapeutic drugsGreater delivery efficiencyBrainClinical applicationStrokeTreatmentTargeted deliveryEfficacyVariety of formulations
2016
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancy
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2011
Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery
Zhou J, Liu J, Cheng CJ, Patel TR, Weller CE, Piepmeier JM, Jiang Z, Saltzman WM. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nature Materials 2011, 11: 82-90. PMID: 22138789, PMCID: PMC4180913, DOI: 10.1038/nmat3187.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGene deliveryNon-viral gene deliveryEfficient gene deliveryGene delivery abilityTargeted gene deliveryHighest molecular weight terpolymerDelivery abilityTargeted deliveryLipofectamine 2000Dialkyl diesterVivo applicationsPolycationic vectorsSpecific ring sizesTRAIL geneHigh efficiencyCharge densityLow charge densityDeliveryPolyethylenimineMinimal toxicityEfficiencyHydrophobicityLactone contentDensityApplications
Academic Achievements and Community Involvement
honor Fellow
International AwardAmerican Institute for Medical and Biological Engineering (AIMBE)Details03/30/2023honor Fellow
International AwardRoyal Society of Chemistry (RSC)Details02/01/2023honor Fellow
International AwardAmerican Heart Association (AHA)Details04/01/2022United Stateshonor Team Science Award
International AwardAssociation for Clinical and Translational ScienceDetails10/01/2020United States
Links & Media
News
- July 15, 2024
Yale Scientists Develop Possible Stealth Cancer Therapy
- October 03, 2023
Large NIH Grant Supports CRISPR-based Gene Therapy Development for Brain Diseases
- May 13, 2022
Research Identifies Genes Responsible for Glioblastoma Cell Development
- June 15, 2021
Yale Cancer Center Study Reveals New Pathway for Brain Tumor Therapy
Get In Touch
Contacts
Locations
Farnam Memorial Building
Academic Office
310 Cedar Street, Ste LH 412A
New Haven, CT 06510
Fax
203.785.2274Appointments
203.785.5327